Literature DB >> 18980446

Development of an ambulatory palliative care pharmacist practice.

Rabia Samady Atayee1, Brookie M Best, Charles E Daniels.   

Abstract

PURPOSE: The roles of a pharmacist in hospice and inpatient palliative care settings have been described. However, no reports of a palliative care pharmacist in an ambulatory care setting have been published. Our objective was to establish a model for incorporating an outpatient clinical pharmacist as part of a multidisciplinary palliative care team.
METHODS: A palliative care pharmacist based out of a retail pharmacy was incorporated as part of a consultative ambulatory palliative care service (known as the Doris A. Howell Service) at the University of California, San Diego Moores Cancer Center. The pharmacist completed all legal requirements to prescribe under a collaborative practice agreement in California (including National Provider Identifier [NPI] and US Drug Enforcement Agency [DEA] US Drug Enforcement Agency (DEA) registration).
RESULTS: From November 2006 through August 2007, the palliative care pharmacist consulted 29 new patients (the average age of patients was 49; range, 20-78 years) who had 114 clinic visits. The most common reason for referral to the palliative care pharmacist was for pain management (27/29; 93%). During the 114 patient clinic visits, 98% (112/114) of the palliative care pharmacist medication recommendations were accepted by the primary care oncologist. Physicians completed a satisfaction survey and reported that the top three useful activities of the Howell Service were: additional time spent with patients without physician present (90.9%), pain and symptom management (81.8%), and psychosocial support (72.7%).
CONCLUSION: This is the first report of a palliative care pharmacist in a retail-based ambulatory care setting. Initial results demonstrate the success of this pilot program.

Entities:  

Mesh:

Year:  2008        PMID: 18980446     DOI: 10.1089/jpm.2008.0023

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  7 in total

Review 1.  The need for community pharmacists in oncology outpatient care: a systematic review.

Authors:  Johannes Thoma; Romána Zelkó; Balázs Hankó
Journal:  Int J Clin Pharm       Date:  2016-04-07

2.  Pharmacist-led, interdisciplinary model for delivery of supportive care in the ambulatory cancer clinic setting.

Authors:  John Valgus; Sandra Jarr; Robert Schwartz; Michelle Rice; Stephen A Bernard
Journal:  J Oncol Pract       Date:  2010-11       Impact factor: 3.840

3.  The Report of the 2020-2021 Professional Affairs Standing Committee: Pharmacists' Unique Role and Integration in Healthcare Settings.

Authors:  Gina D Moore; Anne L Burns; Hannah Fish; Nidhi Gandhi; Diane B Ginsburg; Karl Hess; Clark Kebodeaux; Jody L Lounsbery; Lisa M Meny; Anne Policastri; Matthew G Shimoda; Elizabeth K Tanner; Lynette R Bradley-Baker
Journal:  Am J Pharm Educ       Date:  2021-07-22       Impact factor: 2.047

4.  A community pharmacist medicines optimisation service for patients with advanced cancer pain: a proof of concept study.

Authors:  Zoe Edwards; Michael I Bennett; Alison Blenkinsopp
Journal:  Int J Clin Pharm       Date:  2019-04-09

5.  Advancing Pharmacist Collaborative Care within Academic Health Systems.

Authors:  Linda Awdishu; Renu F Singh; Ila Saunders; Felix K Yam; Jan D Hirsch; Sarah Lorentz; Rabia S Atayee; Joseph D Ma; Shirley M Tsunoda; Jennifer Namba; Christina L Mnatzaganian; Nathan A Painter; Jonathan H Watanabe; Kelly C Lee; Charles D Daniels; Candis M Morello
Journal:  Pharmacy (Basel)       Date:  2019-10-11

6.  The oncology pharmacist as part of the palliative treatment team.

Authors:  Mirjam Crul; Piter Oosterhof
Journal:  Int J Pharm Pract       Date:  2019-10-01

7.  Pharmacists' knowledge, attitude and involvement in palliative care in selected tertiary hospitals in southwestern Nigeria.

Authors:  Rasaq Adisa; Aderonke Tolulope Anifowose
Journal:  BMC Palliat Care       Date:  2019-11-29       Impact factor: 3.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.